Alphyn is developing breakthrough therapies to treat the most challenging, severe, and common skin diseases. Our Zabalafin Platform (AB-101) contains multiple bioactive compounds that power a new class of therapeutics capable of attacking disease in numerous ways. This unique approach enables the development of Multi-Target Therapeutics™ that target multiple diseases, and multiple symptoms and causes of each disease target. Alphyn's lead drug candidate for atopic dermatitis (AD), zabalafin hydrogel, completed Phase 2a clinical trials demonstrating efficacy against both the inflammatory and bacterial components of AD, with minimal side effects and strong patient tolerability for worry-free continuous and long-term use. Clinical trial results show superiority to current commercialized therapeutics and clinical-stage pipeline candidates. Alphyn's second therapeutic candidate is for epidermolysis bullosa, a collection of rare and life-threatening skin diseases.